Consideration of statins for chemoprevention of cutaneous melanoma.
The Skin Cancer Foundation is the only national and international organization devoted exclusively to malignancies of the skin. It conducts public and medical education programs andprovides support for research and professional training to reduce the incidence, morbidity, and mortality of skin cancers. The following article is reprinted from The Melanoma Letter, Vol. 22, No. 3. Outstanding articles from the Foundation's award-winning publications, The Skin Cancer Foundation Journal, The Melanoma Letter, and Sun & Skin News will regularly appear here in upcoming issues. The Skin Cancer Foundation Journal, published annually, is a major part of the Foundation's professional and public education programs. Directed primarily to dermatologists, it also has an extensive readership among the general public. The Melanoma Letter, a widely respected quarterly newsletter for clinicians and researchers, focuses on the diagnosis, treatment, and prevention of the deadliest form of skin cancer. Sun & Skin News, a quarterly newsletter for the lay public, covers a broad range of topics related to skin health, including prevention and treatment of skin cancers and other sun-induced skin damage, the effectiveness of new sunscreen formulas, sunglasses, and the danger of tanning parlors.
Demierre
Marie-France
MF
Skin Oncology Program, Department of Dermatology, Boston University School of Medicine, USA.
D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008545:Melanoma / Q000453:epidemiology / Q000517:prevention & control*; D012878:Skin Neoplasms / Q000453:epidemiology / Q000517:prevention & control*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors